The Tomsk-based company "Artlife," which is the largest producer of gelatin capsules in Russia, plans to enter new sales markets. However, according to Vladimir Mazur, the Governor of the Tomsk Region, certain regulations of the Customs Union are limiting the company's export opportunities.
Russian Minister of Economic Development Maxim Reshetnikov and Governor of the Tomsk Region Vladimir Mazur, during their visit to high-tech production facilities in Tomsk, promised to address the issue of exporting products from the company "Artlife."
"Artlife" is a leader in the wholesale sale of hard gelatin capsules (HGC) in Russia and the Commonwealth of Independent States (CIS). The launch of its own HGC production allowed the company to achieve independence from foreign suppliers.
According to the governor, the company plans to enter new sales markets. He noted that current Customs Union regulations limit the company's ability to export gelatin capsules, which are widely used in the production of pharmaceuticals and dietary supplements. "We agreed with the minister to work on this issue so that the Tomsk enterprise can further develop its production, increase the number of qualified jobs, and boost tax revenues to the budget," Mazur wrote.
As explained by TASS, citing the regional administration's press service and the company, entering new sales markets requires a revision of the maximum allowable levels of residual veterinary drugs in animal-based food products, including gelatin.
Currently, Artlife's products are exported to 27 countries worldwide and across all of Russia. The company’s main production facility — a plant for manufacturing HGC — is located in Tomsk.
The governor also noted that the company has launched a new biotechnology complex in Kaltai, spanning 15,000 square meters. Plans include expanding the facility by an additional 20,000 square meters. Mazur emphasized that such plans are achievable for one of the industry leaders, especially considering that since this year, "Artlife" has become a participant in the national project "Technological Support of the Bioeconomy."
Source: PHARMPROM
